<SEC-DOCUMENT>0001193125-18-319030.txt : 20181106
<SEC-HEADER>0001193125-18-319030.hdr.sgml : 20181106
<ACCEPTANCE-DATETIME>20181106080858
ACCESSION NUMBER:		0001193125-18-319030
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181105
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181106
DATE AS OF CHANGE:		20181106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		181161565

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d627629d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): November&nbsp;5, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>RESTORBIO, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38359</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-3305277</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston Street, 12th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address
of principal executive offices, including zip code) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(857) <FONT STYLE="white-space:nowrap">315-5521</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&nbsp;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&nbsp;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;5, 2018, resTORbio, Inc. (the &#147;Company&#148;) appointed Michael J.
Grissinger to its board of directors (the &#147;Board&#148;), effective immediately. Mr.&nbsp;Grissinger was appointed as a Class&nbsp;II director and will serve until the Company&#146;s annual meeting of stockholders in 2020 or until his successor
is duly elected and qualified. The Company believes that Mr.&nbsp;Grissinger is qualified to serve as a director based on his substantial experience in leading pharmaceutical companies in the industry in which the Company operates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Mr.&nbsp;Grissinger and any other person pursuant to which Mr.&nbsp;Grissinger was elected as a director,
and there are no transactions between Mr.&nbsp;Grissinger and the Company that would require disclosure under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Company&#146;s director compensation program, Mr.&nbsp;Grissinger will receive an annual cash retainer of $30,000 for service on the
Board, which will be paid quarterly in arrears. In addition, under the Company&#146;s director compensation program, upon his election as a director, Mr.&nbsp;Grissinger was granted an option on November&nbsp;5, 2018 to purchase 28,828 shares of the
Company&#146;s common stock at an exercise price per share of $11.82. This option vests as to 33% of the total award on the first anniversary of the grant, with the remainder vesting ratably monthly thereafter for a period of two (2)&nbsp;years,
subject to continued service through such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company has entered into an indemnification agreement with Mr.&nbsp;Grissinger in
connection with his appointment to the Board which is in substantially the same form as that entered into with the other directors of the Company. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify
Mr.&nbsp;Grissinger for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts respectively incurred by him in any action or proceeding arising out of his respective service as one of our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on November&nbsp;5, 2018, Daphne Zohar provided written notice to the Company that she plans to resign from the Board and all committees of the
Board, effective as of the effectiveness of Mr.&nbsp;Grissinger&#146;s appointment to the Board. Ms.&nbsp;Zohar&#146;s decision to resign did not result from any disagreement with the Company on any matter relating to the Company&#146;s operations,
policies or practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Company&#146;s press release announcing these Board changes is attached as Exhibit 99.1 to this Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d627629dex991.htm">Press release, dated November&nbsp;6, 2018. </A></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">resTORbio,&nbsp;Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d627629dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g627629snap0002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio Appoints Michael Grissinger to its Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- Brings extensive business development and licensing experience to resTORbio&#146;s Board - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON, November&nbsp;6, 2018 &#150; </B>resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live
healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of Michael Grissinger to its Board of Directors. He will replace Daphne Zohar, Founder
and CEO of PureTech Health, who is stepping down from the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Michael Grissinger brings significant pharma experience to our Board of Directors.
His background in business development and licensing, particularly his relevant experience on the leadership team of Johnson&nbsp;&amp; Johnson&#146;s immunology franchise, will be beneficial as we advance RTB101 into a planned Phase 3 program to
reduce the incidence of respiratory tract infections (RTIs) in the elderly,&#148; said Chen Schor, <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> President and CEO of resTORbio. &#147;I also want to thank Daphne Zohar for her vision, guidance
and invaluable contributions to resTORbio since our founding.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Grissinger has decades of experience in business development and licensing
leadership roles at global pharmaceutical companies. He formerly held the role of Vice President of Mergers and Acquisitions Operations, Divestitures and Immunology Business Development at Johnson&nbsp;&amp; Johnson where he led the teams
accountable for overseeing all strategic transactions for the pharmaceuticals group. Mr.&nbsp;Grissinger also served as Vice President of Corporate Development and as Vice President of Worldwide Pharmaceutical Business Development and Licensing at
Johnson&nbsp;&amp; Johnson. He has held other roles of increasing responsibility at Johnson&nbsp;&amp; Johnson and began his career as a chemist at The Upjohn Company. Mr.&nbsp;Grissinger holds an M.B.A. from Temple University and a B.S. in
Chemistry from Juniata College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am thrilled to join resTORbio&#146;s Board as the Company continues to build on its leadership position in TORC1
inhibition and the treatment of aging-related diseases. I look forward to contributing to the resTORbio team as we initiate our Phase 3 program for RTIs in the first half of next year and prepare for our Phase 2 trial in patients with
Parkinson&#146;s Disease,&#148; said Mr.&nbsp;Grissinger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About resTORbio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines
with the potential to extend healthy lifespan. resTORbio&#146;s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune,
cardiovascular and central nervous systems. For more information, visit https://www.restorbio.com/. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding our plans to develop and commercialize RTB101 alone or in combination
with everolimus, including the therapeutic potential and clinical benefits thereof, our ongoing and future </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g627629snap0002.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials for RTB101 alone or in combination with everolimus, including the timing of the Phase 3 program for RTIs and the Phase 2 trial for Parkinsons Disease and anticipated results of
these trials, the intended regulatory path for our product candidates and interactions with regulatory authorities, our ability to replicate results achieved in our clinical trials in any future trials, as well as our growth as a Company and the
anticipated contribution of the members of our board of directors and our executives to our operations and programs, constitute forward-looking statements identified by words like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; &#147;anticipate,&#148; or &#147;could&#148; and similar expressions.&nbsp;Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to
differ materially from those anticipated, including, without limitation, risks associated with: the delay of any planned clinical trials and/or development of RTB101, either alone or in combination with everolimus; our ability to successfully
demonstrate the efficacy and safety of our lead product candidate; the clinical results for our lead product candidate which may not support further development of additional indications; uncertainties related to the results of our clinical trials
not being predictive of future results in connection with future trials; and obtaining, maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled &#147;Risk Factors&#148; in the Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed by resTORbio, Inc. with the&nbsp;Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings
with the&nbsp;Securities and Exchange Commission.&nbsp;In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. resTORbio explicitly disclaims
any obligation to update any forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Robinson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-772-7029</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jrobinson@restorbio.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christopher Hippolyte </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosector 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-364-0458</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">christopher.hippolyte@syneoshealth.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g627629snap0002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g627629snap0002.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( $0 ^@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * (;JYCM+9YI71%09
MR[;1^=5"+D[(BI-4XN3*.CZ_8ZU#NMI,2@?/$W#+_B/>M:V'G1?O;'/AL72Q
M*O!Z]C4K ZPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M'O+'.X=?\*11OT % &7KFNVN@VJ7%TLC!WVJJ#)H T894G@CFC.4D4,I]C0
M^@ H * "@ H * &AT+E PW#MGFG9[BNKV(TO+9YS EQ$TH_@#@G\J;A)*[6A
M*J0<N5-7)68(I9B !U)J=RF[;E>/4+*63RX[N%W_ +JR FK=.:5VC-5J<G92
M7WEFH-1&=8U+.P51U). *:5]A-I*[((K^SG?9%=0N_\ =5P35.G.*NT1&M3D
M[1DCGO$7A*37-12Z6\6$+&$VE,]_K79AL6J$.6USS<9E[Q-3G4K:'(^(/"[Z
M!;0S/=+-YC[<!,8XS7I8?%*NVDK6/'Q>!>%BI.5[E70-#;7;R2W6<0E$WY*Y
MSSBKQ%=4(J35S'"85XJ;BG:QU>G>!I-,U&WOGU!&2!MY'EXR!^->?4QRJ0<%
M'<]>CE;HU%4<]O(Y'7M5?6-6EN23Y8.V)?11T_QKTL/25&FHGCXO$/$57/IT
M]"A##+<3)##&TDKG"JHR2:UE)15WL<\8RFU&*NSK=.\#7L=[8R7FPQF3=*B\
M[0!GD^YXKSJF.@XR4#V*.5U(S@ZFU]3T;I7BGTI4U#3K;4[5K>YCW+U!'!4^
MH/8UI3J2I2YHF-:C"M'EFC'T74KFUU*30M3DWW$8W03'_ELGO[UTUZ4905:G
MMU79G'AJ\X5'AJSU6S[K_,S?B-_QXV/_ %U;^5;Y;\4CESGX(>IROA_07UZY
MFA2X$/E(&R5SGG%>AB,0J"3:O<\C!X1XJ3BG:Q8U[PG=:';K<&9)X"VTLHP5
M/;(J,/BXUGRVLS7%Y?/#1Y[W1?\  6J2P:FVG,Y,$REE4_PL/3ZBL<?23A[1
M;HZ,IKRC4]D]G^9JZC_R4S3?^N!_DU>*?3'5S7]G;N$FNH8W_NNX!I 3JZNH
M9&#*>A!R* *U_:65[ ([Z**2(-D"3IF@"RH55"J % P .@% #)IX;=-\TJ1K
MZNP H ;!>6UT/]'N(I<?W'!_E0!-0 4 % !0!YSJ"7L_CN^M+%_+EN4$;2?W
M%P"3^E>U3<(X6,I[(^:K*I+'2A3=F]+]D=/I/A'3M(NH[J%I7N$!&]FZYZ\5
MPU<94JQ<7L>KA\NHX>2G&]S(NA/XN\13V"SO%I=D<2;#]]O\Y_*NB'+A*2G:
M\F<53FQ^(=).T([^9=N/ 6D/;E;99()@/ED#D\^]91Q]5/WM4;SRG#N-H:/N
M.\'ZE=31W6F7S%KFR?;N/4KT_I1C*48M5(;,>75YR4J-3>)GWD4OBGQ9<:;-
M.\=A9#YD0X+FMH-8:@JB7O,YZD98W%.E)VC$N7G@/2WMC]A$EM<J,HX<GGWK
M*&/J)^_JC:IE-%Q_=Z,L>#=3N;_3)8;LEKBUD\MF/4CMFHQM*-.:<=F:9;7G
M5IN,]XNQG_$7_D&V7_78_P#H-;9;\<O0Y\Y_AQ]3*^'G_(:N?^N']:Z,Q_AK
MU.3)_P"-+T.Q\47#6OAJ^D4X8Q[ ?KQ_6O-PL>:M%'M8Z?)AIM=CQ_I7TA\8
M>C^ ]'2WT[^TI$!GGR$)_A3V^M>)CZSE/V:V1]-E6&4*?M7N_P CL*\T]D*
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MT\5^(U%K>QQ:=9$_O-IRS#\S0!U]A90:;8PVENNV*)<#_&D!8H * "@ H *
M"@ H * "@ H * "@ H * "@"CJ.CV&JQ[+RV63'1NC#Z&M:=:=)W@S"MAJ5=
M6J*YS<_P[LG8F"]GB'HP#8_E7=',9K=(\N>34V_=DT)!\.K-&!GOII!Z*H7_
M !HEF,WM$(Y-33]Z39TFFZ+I^DIML[98R>K=6/XUQ5*U2K\3/3HX:E05J:L7
MZQ.@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
I* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
